TrialClinical pharmacology in drug development2025

Pharmacokinetics, Tolerability, and Biomarker Profile of the Neurokinin 3 Receptor Antagonist Fezolinetant in Healthy Japanese Individuals: A 2-Part, Randomized, Phase 1 Study.

Akira Koibuchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.